SMTI
Sanara Medtech Inc
NASDAQ: SMTI · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$18.02
+5.48% today
Updated 2026-06-04
Market cap
$197.03M
P/E ratio
358.33
P/S ratio
1.83x
EPS (TTM)
$0.06
Dividend yield
—
52W range
$16 – $36
Volume
0.1M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+4.0
Quality
C5.0
Profitability
C+5.7
Valuation
C+2/9
Piotroski F-Score
Weak
0.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$34.00
+88.68%
12-Month target
—
—
Intrinsic (DCF)
$46.72
Margin of safety
+58.42%
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 18.60% QoQ
+ 58.42% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 0.68 — distress zone
- Thin margins at -31.20%
- Negative free cash flow $-2.51M
- P/E 358.33x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $45.84M | $64.99M | $86.67M | $103.12M | $107.48M |
| Net income | $-7.94M | $-4.30M | $-9.66M | $-37.56M | $458957.00 |
| EPS | — | — | — | — | $0.06 |
| Free cash flow | $-6.30M | $-3.51M | $-253084.00 | $2.16M | $-2.51M |
| Profit margin | -17.31% | -6.62% | -11.15% | -36.43% | -31.20% |
Peer comparison
Smart narrative
Sanara Medtech Inc trades at $18.02. representing a P/E of 358.33x trailing earnings. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 0.68, it sits in the distress. TTM revenue stands at $107.48M. with profit margins at -31.20%. Our DCF model estimates intrinsic value at $46.72.
Frequently asked questions
What is Sanara Medtech Inc's stock price?
Sanara Medtech Inc (SMTI) trades at $18.02, on a P/E of 358.3x and a P/S of 1.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sanara Medtech Inc overvalued?
Sanara Medtech Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $46.72 versus the $18.02 price, a 58.4% margin of safety on a cash flow basis.
What is the price target of Sanara Medtech Inc (SMTI)?
The 12-month analyst consensus target is $34.00, about 88.7% above the current $18.02. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Sanara Medtech Inc (SMTI)?
Our DCF model estimates intrinsic value at $46.72, a +58.4% margin of safety versus today's $18.02. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Sanara Medtech Inc's revenue?
Sanara Medtech Inc's trailing twelve-month revenue is $107.48M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Sanara Medtech Inc's Altman Z-Score is 0.68, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.83x
ROE2.86%
Beta1.19
50D MA$20.24
200D MA$23.81
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—